Enhancing adoptive CD8 T cell therapy by systemic delivery of tumor associated antigens.

ABSTRACT: Adoptive T-cell transfer (ACT) offers a curative therapeutic option for subsets of melanoma and hematological cancer patients. To increase response rates and broaden the applicability of ACT, it is necessary to improve the post-infusion performance of the transferred T cells. The design of improved treatment strategies includes transfer of cells with a less differentiated phenotype. Such T cell subsets have high proliferative potential but require stimulatory signals in vivo to differentiate into tumor-reactive effector T cells. Thus, combination strategies are needed to support the therapeutic implementation of less differentiated T cells. Here we show that systemic delivery of tumor-associated antigens (TAAs) facilitates in vivo priming and expansion of previously non-activated T cells a

SUBMITTER: Jæhger DE 

PROVIDER: S-EPMC8492729 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature